on Applied DNA Sciences, Inc.
Applied DNA Sciences Complies with Nasdaq Listing Standards
On July 7, 2025, Applied DNA Sciences, Inc. announced it has regained compliance with Nasdaq's listing rule requiring a minimum bid price of $1.00 per share. The notice, received on July 2, confirmed compliance with Nasdaq Capital Market requirements. Consequently, the hearing previously scheduled for July 15 has been cancelled, and the firm's securities will remain listed on Nasdaq.
Applied DNA Sciences specializes in PCR-based DNA technologies. The company, through its subsidiary LineaRx Inc., is advancing its LineaDNA and LineaIVT platforms for nucleic acid-based therapy production.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Applied DNA Sciences, Inc. news